Radical diagnostic could save millions of people at risk of dying from blood loss

October 29, 2020

Engineers at Monash University in Australia have developed a fast, portable and cheap diagnostic that can help deliver urgent treatment to people at risk of dying from rapid blood loss.

In a world-first outcome that could save more than two million lives globally each year, researchers have developed a diagnostic using a glass slide, Teflon film and a piece of paper that can test for levels of fibrinogen concentration in blood in less than four minutes.

Fibrinogen is a protein found in blood that is needed for clotting. When a patient experiences traumatic injury, such as a serious car accident, or major surgery and childbirth complications, fibrinogen is required in their blood to prevent major haemorrhaging and death from blood loss.

Typically, heavily bleeding patients must be transported to a hospital or emergency centre where they undergo diagnostic tests before being treated. These tests are time consuming and costly as they require expensive equipment, specialised/trained personnel and can take up to half an hour.

This new development by researchers at Monash University's Department of Chemical Engineering and BioPRIA (Bioresource Processing Institute of Australia), in collaboration with Haemokinesis, removes the need for centralised hospital equipment to detect, monitor and treat fibrinogen levels - something never achieved until now.

Additionally, this diagnostic can be upscaled into a point-of-care tool and placed in ambulances and other first responder vehicles, in regional and remote locations, and in GP clinics. It takes just four minutes to complete.

Findings were published in the prestigious journal, ACS Sensors.

Professor Gil Garnier, Director of BioPRIA, said this diagnostic will allow emergency doctors and paramedics to quickly and accurately diagnose low levels of fibrinogen in patients, giving them faster access to life-saving treatment to stop critical bleeding.

"When a patient is bleeding heavily and has received several blood transfusions, their levels of fibrinogen drop. Even after dozens of transfusions, patients keep bleeding. What they need is an injection of fibrinogen. However, if patients receive too much fibrinogen, they can also die," Professor Garnier said.

"There are more than 60 tests that can measure fibrinogen concentration. However, these tests require importable machinery on hospital table tops to use. This means that critical time has to be spent transporting heavily bleeding patients to a hospital - before they even undergo a 30 minute diagnosis."

PhD candidate in the Department of Chemical Engineering and research co-author, Marek Bialkower, said the implications for this diagnostic are significant.

"Our diagnostic can eliminate the preparation time, labour and transportation difficulties of traditional techniques used in the hospital, Mr Bialkower said.

"It can diagnose hypofibrinogenemia in critically bleeding patients anywhere in the world, and can drastically reduce the time to treatment needed for fibrinogen replacement therapy. The test can take less than four minutes, about five times faster than the current gold standard methods."

The test works by placing a pre-mixed droplet of a blood sample and an enzyme solution onto a solid surface, allowing it to clot, and then dropping a paper strip on top. The further that blood moves down the strip of paper, the lower the fibrinogen concentration.

The diagnostic can work with a variety of blood conditions. Furthermore, diluting blood samples not only increases the test's sensitivity, but also eliminates the effect of interfering substances in the blood.

Hypofibrinogenemia (insufficient fibrinogen to enable effective clotting) in critical bleeding is common. More than 20 per cent of major trauma patients have hyperfibrinogenemia.

Dr Clare Manderson, Research Fellow in the Monash Department of Chemical Engineering and co-author of the study, said the early diagnosis of hypofibrinogenemia could stop bleeding in these patients and save their lives.

"The development of the world's first handheld fibrinogen diagnostic is a game changer for the millions of people who die each year from critical blood loss. It will also ease pressure on emergency departments knowing that this life-saving treatment can be delivered on site and in quick time," Dr Manderson said.

"Our capacity to develop this diagnostic using cheap and readily available materials means it can be easily commercialised for use across the world."
-end-
Professor Gil Garnier and Marek Bialkower (BioPRIA, Department of Chemical Engineering) led this research titled: 'Paper diagnostic for direct measurement of fibrinogen concentration in whole blood'. They were supported by Dr Clare Manderson and Dr Heather McLiesh (BioPRIA, Department of Chemical Engineering), and Associate Professor Rico Tabor (School of Chemistry).

The research was funded by an ARC Linkage grant and Haemokinesis, which owns the intellectual property.

To download a copy of the paper, please visit: https://doi.org/10.1021/acssensors.0c01937

MEDIA ENQUIRIES

Leigh Dawson
T: +61 455 368 260 E: media@monash.edu
For more Monash media stories, visit our news and events site

Monash University

Related Chemical Engineering Articles from Brightsurf:

Strain engineering of 2D semiconductor and graphene
Strain engineering can significantly manipulate the two-dimensional (2D) materials' electronic and optical properties, which endow it the potential applications in optoelectronics and nanophotonics.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Next frontier in bacterial engineering
A new technique overcomes a serious hurdle in the field of bacterial design and engineering.

COVID-19 and the role of tissue engineering
Tissue engineering has a unique set of tools and technologies for developing preventive strategies, diagnostics, and treatments that can play an important role during the ongoing COVID-19 pandemic.

Engineering the meniscus
Damage to the meniscus is common, but there remains an unmet need for improved restorative therapies that can overcome poor healing in the avascular regions.

Artificially engineering the intestine
Short bowel syndrome is a debilitating condition with few treatment options, and these treatments have limited efficacy.

Scientists use molecular tethers, chemical 'light sabers' for tissue engineering
Researchers at the University of Washington unveiled a new strategy to keep proteins intact and functional in synthetic biomaterials for tissue engineering.

Breakthrough in blood vessel engineering
Growing functional blood vessel networks is no easy task. Previously, other groups have made networks that span millimeters in size.

Next-gen batteries possible with new engineering approach
Dramatically longer-lasting, faster-charging and safer lithium metal batteries may be possible, according to Penn State research, recently published in Nature Energy.

A new way to do metabolic engineering
University of Illinois researchers have created a novel metabolic engineering method that combines transcriptional activation, transcriptional interference, and gene deletion, and executes them simultaneously, making the process faster and easier.

Read More: Chemical Engineering News and Chemical Engineering Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.